Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383 | 0.89 | — | — | |
| SCHEMBL2542186 | 0.86 | — | — | |
| SCHEMBL2538056 | 0.86 | — | — | |
| SCHEMBL2545707 | 0.86 | — | — | |
| SCHEMBL2543714 | 0.86 | — | — | |
| Charcoal, Activated SCHEMBL526932 | 0.86 | — | — | |
| Phosphoric Acid SCHEMBL10534010 | 0.86 | KDM4E (0.37) | PGK1PGK2KDM4EMMP2THRB | |
| Ammonia Solution, Strong SCHEMBL2540910 | 0.86 | — | — | |
| SCHEMBL8059753 | 0.86 | — | — | |
| Rubidium SCHEMBL2546208 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104093724-B | Mixture of dialkylphosphinic acids and alkylphosphonic acids, method for the production thereof and use thereof | 科莱恩金融(BVI)有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-5183815-A | Bone acting agents | MERCK & CO., INC. (US) | 1993-02-02 | — | — | US | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| CN-106796398-B | Lithographic printing plate precursor comprising (ethylene-vinyl acetal) copolymer | 爱克发有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-107848959-A | The phenoxyphenylamidineand of halogen substitution and its purposes as fungicide | 拜耳农作物科学股份公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-106062094-B | Greenhouse apparatus | 爱科琪盛欧洲股份公司 | 2018-03-13 | — | — | CN | disclosed |
| CN-104093724-B | Mixture of dialkylphosphinic acids and alkylphosphonic acids, method for the production thereof and use thereof | 科莱恩金融(BVI)有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-8193167-B2 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100273742-A1 | Pharmacologically Active Agents Containing Esterified Phosphonates and Methods for Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | US | disclosed |
| US-7652001-B2 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2005090370-A1 | PHARMACOLOGICALLY ACTIVE AGENTS CONTAINING ESTERIFIED PHOSPHONATES AND METHODS FOR USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | US ARMY, SECRETARY OF THE ARMY | 2005-09-01 | — | — | US | disclosed |
| US-20050026223-A1 | Method and compositions for increasing bone mass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2005-02-03 | — | — | US | disclosed |
| US-20040224884-A1 | Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof | MANOLAGAS STAVROS C (US) | 2004-11-11 | — | — | US | disclosed |
| EP-0831845-B1 | DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS | ELIZANOR BIOPHARMACEUTICALS IN (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6416737-B1 | SCREENING COMPOUNDS (BISPHOSPHONATES SUCH AS ALENDRONATES) THAT INCREASE BONE STRENGTH BY CONTACTING OSTEOCYTES WITH THE COMPOUND, MEASURING THE APOPTOSIS OF THE CELLS, AND SELECTING THE COMPOUND THAT INHIBITS APOPTOSIS IN OSTEOBLASTS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2002-07-09 | — | — | US | disclosed |
| EP-0643071-B1 | COMPOUND FOR INHIBITING BONE RESORPTION AND ACCELERATING OSTEOGENESIS | ISKRA INDUSTRY CO LTD (JP) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000028982-A2 | INCREASING BONE STRENGTH WITH SELECTED BISPHOSPHONATES | THE BOARD OF TRUSTEES FOR THE UNIVERSITY OF ARKANSAS (US) | 2000-05-25 | — | — | WO | disclosed |
| US-5183815-A | Bone acting agents | MERCK & CO., INC. (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273742-A1 | Pharmacologically Active Agents Containing Esterified Phosphonates and Methods for Use Thereof | PHPT1, PPIP5K2, PHOSPHO1 | PGK1 162/4885PGK2 212/4885KDM4E 2970/4885 |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | PHPT1, PPIP5K2, PHOSPHO1 | PGK1 162/4885PGK2 212/4885KDM4E 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.